Comparison of efficacy and safety of adjunct treatments to levodopa in patients with Parkinson’s disease and wearing-off: A network meta-analysis of randomized, double-blind trials
Objective: To determine the rankings for efficacy and tolerability of levodopa adjuncts in patients with Parkinson’s disease (PD) and wearing-off by network meta-analysis. Background: When…Diagnosed and Drug-Treated Prevalence of Essential Tremor in Pediatric Patients: Retrospective Analyses of Two US Healthcare Claims Databases
Objective: Estimate the prevalence of diagnosed and drug-treated essential tremor (ET) in the pediatric population using 2 US healthcare claims databases. Background: An ET diagnosis…Preclinical Characterization of Suvecaltamide for Essential Tremor
Objective: To characterize the in vitro T-type calcium (CaV3) channel target pharmacology and in vivo anti-tremor profile of suvecaltamide (JZP385, CX-8998). Background: CaV3 channels, a…Initial experience with levodopa-entacapone-carbidopa intestinal gel infusion (LECIG) for the management of advanced Parkinson’s disease in Slovenia
Objective: To study the initial experience with levodopa-entacapone-carbidopa intestinal gel infusion (LECIG) in routine clinical practice at two University Medical Centers in Slovenia. Background: The…Statin use and incidence of Parkinson’s disease in women from the French E3N cohort study
Objective: To examine whether incident statin use is associated with lower Parkinson’s disease (PD) incidence while considering the potential for reverse causation. Background: Drug repurposing…Phase 2 study evaluating safety, PK/PD, biomarkers, and efficacy of ANX005 in patients with Huntington’s disease (HD)
Objective: To assess the safety, PK/PD, exploratory biomarkers, and efficacy of ANX005 in patients with, or at risk for, manifest HD. Background: Increased complement activation…Long-Term Safety and Efficacy of Apomorphine Sublingual Film for “OFF” Episodes in Parkinson’s Disease
Objective: Evaluate long-term safety (LTS), tolerability, and efficacy of apomorphine sublingual film (APL) for on-demand treatment of “OFF” episodes in patients with Parkinson’s disease (PD).…Pilot study of Phenotype of Antisense-Oligonucleotide-(ASO)-knockdown of Cerebral-Dopamine-Neurotrophic-Factor (CDNF) as Parkinson Disease model : implications for PD and related Dementia Therapeutics
Objective: Our objective is twofold: 1)to examine whether CDNF-ASO paradigm can induce a unique phenotype mimicking PD/PDD/LBW in the rodent species; 2) to evaluate whether…Apomorphine Sublingual Film for “OFF” Episodes in Parkinson’s Disease: Impact of Concomitant Antiemetics on Nausea and Vomiting
Objective: Analyze the effect of concomitant trimethobenzamide (TMB) on nausea and vomiting rates in patients with Parkinson’s disease (PD) receiving apomorphine sublingual film (APL) for…Motor and non-motor effects of mevidalen in Lewy Body Dementia as measured by the Movement Disorder Society’s Unified Parkinson’s Disease Rating Scale (MDS-UPDRS)
Objective: To assess the motor and non-motor effects of mevidalen in patients with Lewy Body Dementia (LBD) as measured by the MDS-UPDRS. Background: Mevidalen is…
- « Previous Page
- 1
- …
- 10
- 11
- 12
- 13
- 14
- …
- 34
- Next Page »